Skip to content
Screener

AbCellera Biologics Inc. ABCL Shares (Diluted)

Shares (Diluted) at other companies

Schrodinger logo
SchrodingerSDGR
75.8M+3.2%
Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
61.7M+3.4%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
532.5M+27.6%
Absci Corporation logo
Absci CorporationABSI
153M+22.9%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
43.6M+303%
Xencor logo
XencorXNCR
75.9M+2.1%

Other financials

Income statement

See full
Revenue$4.1M-76.3%
Operating income-$62.8M-26.6%
Net income-$55.4M-59.6%
EPS (diluted)-$0.18-50.0%

Balance sheet

See full
Cash & equivalents$145.1M+23.5%
Total debt$135.6M-4.5%
Total equity$896.0M-11.0%
Total assets$1.3B-6.7%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$2.1M-84.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$1.99B+62.2%
Enterprise value$1.98B+58.2%
P/S30.1×-7.3×

Profitability

See full
Operating margin-340.3%-127pp
Net margin-248.8%-83.6pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-17.3%+2.1pp
Debt / equity0.2×0.0×
Current ratio12.8×+1.7×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:28 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001703057-26-000046
Line itemThree months ended June 30, 2025Three months ended June 30, 2026Six months ended June 30, 2025Six months ended June 30, 2026
Foreign currency translation adjustment4,341(733)1,7211,082
Comprehensive loss$(30,386)$(56,160)$(78,627)$(97,510)
Net loss per share
Basic$(0.12)$(0.18)$(0.27)$(0.32)
Diluted$(0.12)$(0.18)$(0.27)$(0.32)
Weighted-average common shares outstanding
Basic298,508,601305,557,294298,105,760304,329,623
Diluted298,508,601305,557,294298,105,760304,329,623

Item 1. Financial Statements (Unaudited)

FAQ

What is AbCellera Biologics Inc.'s shares (diluted)?
AbCellera Biologics Inc. (ABCL) reported shares (diluted) of 305.6M in Q2 2026.
How has AbCellera Biologics Inc.'s shares (diluted) changed year-over-year?
AbCellera Biologics Inc.'s shares (diluted) increased by 2.4% year-over-year, from 298.5M to 305.6M.
What is the long-term trend for AbCellera Biologics Inc.'s shares (diluted)?
Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s shares (diluted) has grown at a 0.1% compound annual growth rate (CAGR), from 1.2B to 1.2B.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about AbCellera Biologics Inc.'s shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude